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| BACKGROUND
Leishmaniasis is a parasitic disease affecting 540 million people worldwide, with 1.3 million new cases reported annually and about 30 000 deaths per year.
[S1] In immune competent hosts, for example humans or C57BL/6 mice, infection with L. major results in CD4 + Th1/CD8 + Tc1 immunity with long-lasting resistance, whereas in BALB/c mice or immune-suppressed humans, progressive, disseminated disease associated with Th2/Treg/Th17-driven immune response is observed. [1, 2] Together with CD4 + T cells, IFN-γ-producing CD8 + Tc1 cells play an important role against L. major infections. [3] In endemic areas, "leishmanization" with viable parasites is performed to protect humans against re-challenge with the same Leishmania subspecies. [4, 5] 
| QUESTION ADDRESSED
Within the present study, we now focused on predicting MHC Irestricted peptides that could be used as vaccine candidates in resistant C57BL/6 mice. This in turn would aid the development of a vaccine against human cutaneous leishmaniasis.
| EXPERIMENTAL DESIGN
The entire genome of L. major encodes for 8265 proteins ( Figure S1 ).
[S2]
First, we evaluated all 8-mer and 9-mer peptides derived from these proteins for their predicted affinity to bind to C57BL/6-specific MHC Imolecules using the computer-based algorithm SYFPEITHI. 
| RESULTS
As expected, the majority of predicted epitopes exhibited a low Interestingly, however and in line with others, [7] Figure 1C ,D, the number of predicted epitopes from these eight proteins with high scores was relatively small compared to the total number of potential L. major epitopes for each score.
| CONCLUSIONS
Our results provide an in-depth resource for predicted MHC I epitopes derived from L. major proteins by SYFPEITHI. Using the C57BL/6 mouse model for cutaneous leishmaniasis best resembling human disease, we show that most likely several major "immunodominant" epitopes of L. major (as defined by higher predicted scores) have not been identified so far. Thus, computer-based algorithms may serve as a helpful tool for the identification of peptides and proteins in general.
Nevertheless, these results represent theoretical binding of the peptides towards MHC I-molecules and thus need to be further analysed in in vitro and in vivo studies for their capacity to be used as a vaccine.
Future investigations using a combination of different prediction algorithms for the identification of immunodominant peptides/protein will further improve predictions. In the end, this would increase the number of predicted epitopes and include peptides with ˃9 amino acid residues [7, 8, 9] (Data S1). Taken together, mouse-or human-specific epitopes identified in silico hold potential as strong vaccine candidates against cutaneous leishmaniasis. Predictions of human-specific epitopes will need to be performed. 
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